IDEAS home Printed from https://ideas.repec.org/r/wly/hlthec/v19y2010i4p422-437.html
   My bibliography  Save this item

International survey on willingness‐to‐pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Irina A. Denisova & Tatiana V. Chubarova & Irina E. Bogatova & Sergei A. Vartanov & Valerian G. Kucheryanu & ViÑ tor M. Polterovich & Natalia A. Turdyeva & Marina V. Shakleina, 2020. "Estimating economic efficiency of preclinical diagnostics of Parkinson disease with cost-utility approach," Population and Economics, ARPHA Platform, vol. 4(3), pages 111-127, December.
  2. Saara Huoponen & Marja Blom, 2015. "A Systematic Review of the Cost-Effectiveness of Biologics for the Treatment of Inflammatory Bowel Diseases," PLOS ONE, Public Library of Science, vol. 10(12), pages 1-23, December.
  3. Fischer, Barbara & Telser, Harry & Zweifel, Peter & von Wyl, Viktor & Beck, Konstantin & Weber, Andreas, 2023. "The value of a QALY towards the end of life and its determinants: Experimental evidence," Social Science & Medicine, Elsevier, vol. 326(C).
  4. Amaia Malet-Larrea & Estíbaliz Goyenechea & Miguel A. Gastelurrutia & Begoña Calvo & Victoria García-Cárdenas & Juan M. Cabases & Aránzazu Noain & Fernando Martínez-Martínez & Daniel Sabater-Hernández, 2017. "Cost analysis and cost-benefit analysis of a medication review with follow-up service in aged polypharmacy patients," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(9), pages 1069-1078, December.
  5. Dastan Bamwesigye, 2023. "Willingness to Pay for Alternative Energies in Uganda: Energy Needs and Policy Instruments towards Zero Deforestation 2030 and Climate Change," Energies, MDPI, vol. 16(2), pages 1-21, January.
  6. Jun Li & Benjamin H K Yip & Chichiu Leung & Wankyo Chung & Kin On Kwok & Emily Y Y Chan & Engkiong Yeoh & Puihong Chung, 2018. "Screening for latent and active tuberculosis infection in the elderly at admission to residential care homes: A cost-effectiveness analysis in an intermediate disease burden area," PLOS ONE, Public Library of Science, vol. 13(1), pages 1-18, January.
  7. Graves, Nicholas & Clare, Gina & Haines, Mary & Bird, Robert, 2010. "A policy case study of blood in Australia," Social Science & Medicine, Elsevier, vol. 71(9), pages 1677-1682, November.
  8. Darryn Marks & Leanne Bisset & Tracy Comans & Michael Thomas & Shu Kay Ng & Shaun O’Leary & Philip G Conaghan & Paul A Scuffham, 2016. "Increasing Capacity for the Treatment of Common Musculoskeletal Problems: A Non-Inferiority RCT and Economic Analysis of Corticosteroid Injection for Shoulder Pain Comparing a Physiotherapist and Orth," PLOS ONE, Public Library of Science, vol. 11(9), pages 1-20, September.
  9. Claudia Schulz & Gisela Büchele & Raphael S. Peter & Dietrich Rothenbacher & Christian Brettschneider & Ulrich C. Liener & Clemens Becker & Kilian Rapp & Hans-Helmut König, 2021. "Health-economic evaluation of collaborative orthogeriatric care for patients with a hip fracture in Germany: a retrospective cohort study using health and long-term care insurance claims data," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(6), pages 873-885, August.
  10. Ziebarth, N. R. & Schmitt, M. & Karlsson, M., 2013. "The short-term population health effects of weather and pollution: implications of climate change," Health, Econometrics and Data Group (HEDG) Working Papers 13/34, HEDG, c/o Department of Economics, University of York.
  11. Ryen, Linda & Svensson, Mikael, 2014. "The Willingness to Pay for a QALY: a Review of the Empirical Literature," Karlstad University Working Papers in Economics 12, Karlstad University, Department of Economics.
  12. Susan Geertshuis & Otto Krickl, 2013. "Value Judgements and Continuing Education," International Journal of Management, Knowledge and Learning, International School for Social and Business Studies, Celje, Slovenia, vol. 2(1), pages 123-141.
  13. Shota Saito & Motoi Azumi & Yusuke Muneoka & Katsuhiko Nishino & Takashi Ishikawa & Yuichi Sato & Shuji Terai & Kouhei Akazawa, 2018. "Cost-effectiveness of combined serum anti-Helicobacter pylori IgG antibody and serum pepsinogen concentrations for screening for gastric cancer risk in Japan," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(4), pages 545-555, May.
  14. Maria Rubio-Valera & María Teresa Peñarrubia-María & Maria Iglesias-González & Martin Knapp & Paul McCrone & Marta Roig & Ramón Sabes-Figuera & Juan V. Luciano & Juan M. Mendive & Ana Gabriela Murruga, 2019. "Cost-effectiveness of antidepressants versus active monitoring for mild-to-moderate major depressive disorder: a multisite non-randomized-controlled trial in primary care (INFAP study)," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(5), pages 703-713, July.
  15. Andrea Iannaccone & Thomas Marwick, 2015. "Cost Effectiveness of Transcatheter Aortic Valve Replacement Compared with Medical Management or Surgery for Patients with Aortic Stenosis," Applied Health Economics and Health Policy, Springer, vol. 13(1), pages 29-45, February.
  16. Ronald Wielage & Megha Bansal & J. Andrews & Robert Klein & Michael Happich, 2013. "Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective," Applied Health Economics and Health Policy, Springer, vol. 11(3), pages 219-236, June.
  17. John Paul Ekwaru & Arto Ohinmaa & Bach Xuan Tran & Solmaz Setayeshgar & Jeffrey A Johnson & Paul J Veugelers, 2017. "Cost-effectiveness of a school-based health promotion program in Canada: A life-course modeling approach," PLOS ONE, Public Library of Science, vol. 12(5), pages 1-13, May.
  18. Hoa‐Thi‐Minh Nguyen & Tom Kompas & Roslyn I. Hickson, 2014. "Aid and the Control of Tuberculosis in Papua New Guinea: Is Australia's Assistance Cost‐Effective?," Asia and the Pacific Policy Studies, Wiley Blackwell, vol. 1(2), pages 364-378, May.
  19. Björn Sund & Mikael Svensson, 2018. "Estimating a constant WTP for a QALY—a mission impossible?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(6), pages 871-880, July.
  20. Hui Jun Zhou & Yock Young Dan & Nasheen Naidoo & Shu Chuen Li & Khay Guan Yeoh, 2013. "A Cost-Effectiveness Analysis Evaluating Endoscopic Surveillance for Gastric Cancer for Populations with Low to Intermediate Risk," PLOS ONE, Public Library of Science, vol. 8(12), pages 1-10, December.
  21. Thomas Grochtdreis & Hans-Helmut König & Alexander Dobruschkin & Gunhild von Amsberg & Judith Dams, 2018. "Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review," PLOS ONE, Public Library of Science, vol. 13(12), pages 1-25, December.
  22. Jorge Barros-Garcia-Imhof & Andrés Jiménez-Alfonso & Inés Gómez-Acebo & María Fernández-Ortiz & Jéssica Alonso-Molero & Javier Llorca & Alejandro Gonzalez-Castro & Trinidad Dierssen-Sotos, 2022. "Perception of Medical Students on the Need for End-of-Life Care: A Q-Methodology Study," IJERPH, MDPI, vol. 19(13), pages 1-16, June.
  23. Dan Cai & Si Shi & Shan Jiang & Lei Si & Jing Wu & Yawen Jiang, 2022. "Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(4), pages 607-615, June.
  24. Khachapon Nimdet & Nathorn Chaiyakunapruk & Kittaya Vichansavakul & Surachat Ngorsuraches, 2015. "A Systematic Review of Studies Eliciting Willingness-to-Pay per Quality-Adjusted Life Year: Does It Justify CE Threshold?," PLOS ONE, Public Library of Science, vol. 10(4), pages 1-16, April.
  25. Lotte Soeteman & Job Exel & Ana Bobinac, 2017. "The impact of the design of payment scales on the willingness to pay for health gains," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(6), pages 743-760, July.
  26. Linda Ryen & Stefan Lundqvist & Åsa Cider & Mats Börjesson & Maria E. H. Larsson & Lars Hagberg, 2023. "Cost-Effectiveness of Prolonged Physical Activity on Prescription in Previously Non-Complying Patients: Impact of Physical Activity Mediators," IJERPH, MDPI, vol. 20(5), pages 1-14, February.
  27. Marisa Holubar & Maria Christina Stavroulakis & Yvonne Maldonado & John P A Ioannidis & Despina Contopoulos-Ioannidis, 2017. "Impact of vaccine herd-protection effects in cost-effectiveness analyses of childhood vaccinations. A quantitative comparative analysis," PLOS ONE, Public Library of Science, vol. 12(3), pages 1-22, March.
  28. Vincent T Janmaat & Marco J Bruno & Suzanne Polinder & Sylvie Lorenzen & Florian Lordick & Maikel P Peppelenbosch & Manon C W Spaander, 2016. "Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell Carcinoma," PLOS ONE, Public Library of Science, vol. 11(4), pages 1-10, April.
  29. Akazawa, Manabu & Yongue, Julia & Ikeda, Shunya & Satoh, Toshihiko, 2014. "Considering economic analyses in the revision of the preventive vaccination law: A new direction for health policy-making in Japan?," Health Policy, Elsevier, vol. 118(1), pages 127-134.
  30. Kamran Bagheri Lankarani & Sulmaz Ghahramani & Najmeh Moradi & Hadi Raeisi Shahraki & Farhad Lotfi & Behnam Honarvar, 2018. "Willingness-to-Pay for One Quality-Adjusted Life-Year: A Population-Based Study from Iran," Applied Health Economics and Health Policy, Springer, vol. 16(6), pages 837-846, December.
  31. David Brain & Ruth Tulleners & Xing Lee & Qinglu Cheng & Nicholas Graves & Rosana Pacella, 2019. "Cost-effectiveness analysis of an innovative model of care for chronic wounds patients," PLOS ONE, Public Library of Science, vol. 14(3), pages 1-13, March.
  32. Linda Ryen & Mikael Svensson, 2015. "The Willingness to Pay for a Quality Adjusted Life Year: A Review of the Empirical Literature," Health Economics, John Wiley & Sons, Ltd., vol. 24(10), pages 1289-1301, October.
  33. Afentoula G. Mavrodi & Vassilis H. Aletras, 2019. "Preliminary Results of a Healthcare Contingent Valuation Study in Greece," International Journal of Finance, Insurance and Risk Management, International Journal of Finance, Insurance and Risk Management, vol. 9(3-4), pages 3-16.
  34. Hiroshi Tamura & Rei Goto & Yoko Akune & Yoshimune Hiratsuka & Shusuke Hiragi & Masakazu Yamada, 2015. "The Clinical Effectiveness and Cost-Effectiveness of Screening for Age-Related Macular Degeneration in Japan: A Markov Modeling Study," PLOS ONE, Public Library of Science, vol. 10(7), pages 1-20, July.
  35. Christian R. C. Kouakou & Thomas G. Poder, 2022. "Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(2), pages 277-299, March.
  36. Henrik Andersson & James K. Hammitt & Kristian Sundström, 2015. "Willingness to Pay and QALYs: What Can We Learn about Valuing Foodborne Risk?," Journal of Agricultural Economics, Wiley Blackwell, vol. 66(3), pages 727-752, September.
  37. Kristian Bolin & Lars Forsgren, 2012. "The Cost Effectiveness of Newer Epilepsy Treatments," PharmacoEconomics, Springer, vol. 30(10), pages 903-923, October.
  38. Jean de Kervasdoué & Laurence Hartmann, 2016. "Economic impact of hearing loss in France and developed countries," Working Papers hal-02105131, HAL.
  39. Ava A John-Baptiste & Wei Wu & Paula Rochon & Geoffrey M Anderson & Chaim M Bell, 2013. "A Systematic Review and Methodological Evaluation of Published Cost-Effectiveness Analyses of Aromatase Inhibitors versus Tamoxifen in Early Stage Breast Cancer," PLOS ONE, Public Library of Science, vol. 8(5), pages 1-9, May.
  40. Nicholas Illenberger & Nandita Mitra & Andrew J. Spieker, 2022. "A regression framework for a probabilistic measure of cost‐effectiveness," Health Economics, John Wiley & Sons, Ltd., vol. 31(7), pages 1438-1451, July.
  41. Andrew Gallagher & Violetta Shersher & Duncan Mortimer & Helen Truby & Terry Haines, 2023. "The Cost-Effectiveness of Adjunctive Lifestyle Interventions for the Management of Cancer: A Systematic Review," Applied Health Economics and Health Policy, Springer, vol. 21(2), pages 225-242, March.
  42. Hidetoshi Shibahara & Takeru Shiroiwa & Megumi Ishiguro & Masato Nakamura & Junichi Hasegawa & Shigeki Yamaguchi & Yuriko Masuda & Junichi Sakamoto & Naohiro Tomita & Takashi Fukuda, 2022. "Cost-effectiveness of 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer: preplanned cost-effectiveness analysis of the JFMC37-0801 study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(7), pages 1159-1171, September.
  43. Eric D. Carlström & Elisabeth Hansson Olofsson & Lars-Eric Olsson & Jan Nyman & Inga-Lill Koinberg, 2017. "The unannounced patient in the corridor: trust, friction and person-centered care," International Journal of Health Planning and Management, Wiley Blackwell, vol. 32(1), pages 1-16, January.
  44. Shu-ling Hoshi & Masahide Kondo & Ichiro Okubo, 2015. "Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the ," PLOS ONE, Public Library of Science, vol. 10(10), pages 1-16, October.
  45. An Tran-Duy & Annelies Boonen & Wietske Kievit & Piet Riel & Mart Laar & Johan Severens, 2014. "Modelling Outcomes of Complex Treatment Strategies Following a Clinical Guideline for Treatment Decisions in Patients with Rheumatoid Arthritis," PharmacoEconomics, Springer, vol. 32(10), pages 1015-1028, October.
  46. Bobinac, Ana & van Exel, N. Job A. & Rutten, Frans F.H. & Brouwer, Werner B.F., 2012. "GET MORE, PAY MORE? An elaborate test of construct validity of willingness to pay per QALY estimates obtained through contingent valuation," Journal of Health Economics, Elsevier, vol. 31(1), pages 158-168.
  47. Svensson, Mikael & Hultkrantz, Lars, 2012. "The Willingness to Pay for a QALY - Results based on value of statistical life estimates in Sweden," Karlstad University Working Papers in Economics 2, Karlstad University, Department of Economics.
  48. Yun-Kyung Kim & Joon Young Song & Hyeongap Jang & Tae Hyun Kim & Heejo Koo & Lijoy Varghese & Euna Han, 2018. "Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea," PharmacoEconomics, Springer, vol. 36(12), pages 1475-1490, December.
  49. Shah, Koonal K. & Tsuchiya, Aki & Wailoo, Allan J., 2018. "Valuing health at the end of life: A review of stated preference studies in the social sciences literature," Social Science & Medicine, Elsevier, vol. 204(C), pages 39-50.
  50. Penny Reeves & Kim Edmunds & Christopher Levi & Longting Lin & Xin Cheng & Richard Aviv & Tim Kleinig & Kenneth Butcher & Jingfen Zhang & Mark Parsons & Andrew Bivard, 2018. "Cost-effectiveness of targeted thrombolytic therapy for stroke patients using multi-modal CT compared to usual practice," PLOS ONE, Public Library of Science, vol. 13(10), pages 1-11, October.
  51. Najme Moradi & Arash Rashidian & Shirin Nosratnejad & Alireza Olyaeemanesh & Marzieh Zanganeh & Leila Zarei, 2019. "The Worth of a Quality-Adjusted Life-Year in Patients with Diabetes: An Investigation Study using a Willingness-to-Pay Method," PharmacoEconomics - Open, Springer, vol. 3(3), pages 311-319, September.
  52. Robinson, Angela & Gyrd-Hansen, Dorte & Bacon, Philomena & Baker, Rachel & Pennington, Mark & Donaldson, Cam, 2013. "Estimating a WTP-based value of a QALY: The ‘chained’ approach," Social Science & Medicine, Elsevier, vol. 92(C), pages 92-104.
  53. Lixian Zhong & Vickie Pon & Sandy Srinivas & Nicole Nguyen & Meghan Frear & Sherry Kwon & Cynthia Gong & Robert Malmstrom & Leslie Wilson, 2013. "Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis," PLOS ONE, Public Library of Science, vol. 8(5), pages 1-11, May.
  54. S. Laplante & F. X. Liu & B. Culleton & A. Bernardo & Denise King & P. Hudson, 2016. "The Cost Effectiveness of High-Dose versus Conventional Haemodialysis: a Systematic Review," Applied Health Economics and Health Policy, Springer, vol. 14(2), pages 185-193, April.
  55. Christine Arentz, 2011. "Medizinisch-technischer Fortschritt im Gesundheitswesen: Zentrale Kosten-Nutzen-Bewertung ohne Alternative?," Otto-Wolff-Institut Discussion Paper Series 01/2011, Otto-Wolff-Institut für Wirtschaftsordnung, Köln, Deutschland.
  56. Markiewicz, Katarzyna & van Til, Janine A. & Steuten, Lotte M.G. & IJzerman, Maarten J., 2016. "Commercial viability of medical devices using Headroom and return on investment calculation," Technological Forecasting and Social Change, Elsevier, vol. 112(C), pages 338-346.
  57. Ava John-Baptiste & Man Yeung & Victoria Leung & Gabrielle Velde & Murray Krahn, 2012. "Cost Effectiveness of Hepatitis C-Related Interventions Targeting Substance Users and Other High-Risk Groups," PharmacoEconomics, Springer, vol. 30(11), pages 1015-1034, November.
  58. Shiroiwa, Takeru & Fukuda, Takashi & Ikeda, Shunya & Takura, Tomoyuki, 2017. "New decision-making processes for the pricing of health technologies in Japan: The FY 2016/2017 pilot phase for the introduction of economic evaluations," Health Policy, Elsevier, vol. 121(8), pages 836-841.
  59. Samuel Herzog & Marian Shanahan & Peter Grimison & Anh Tran & Nicole Wong & Nicholas Lintzeris & John Simes & Martin Stockler & Rachael L. Morton, 2018. "Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis," PharmacoEconomics, Springer, vol. 36(1), pages 67-78, January.
  60. Shafie, A.A. & Hassali, M.A., 2013. "Willingness to pay for voluntary community-based health insurance: Findings from an exploratory study in the state of Penang, Malaysia," Social Science & Medicine, Elsevier, vol. 96(C), pages 272-276.
  61. Reece Holbrook & Lucas Higuera & Kael Wherry & Dave Phay & Yu-Cheng Hsieh & Kuo-Hung Lin & Yen-Bin Liu, 2020. "Implantable cardioverter defibrillator therapy is cost effective for primary prevention patients in Taiwan: An analysis from the Improve SCA trial," PLOS ONE, Public Library of Science, vol. 15(11), pages 1-12, November.
  62. Beth Woods & Paul Revill & Mark Sculpher & Karl Claxton, 2015. "Country-level cost-effectiveness thresholds: initial estimates and the need for further research," Working Papers 109cherp, Centre for Health Economics, University of York.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.